Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.98M | $7.96M | $6.90M | $3.38M | — | — | — | — | $0.00 | $0.00 |
| Revenue growth | — | 99.8% | -13.4% | -51.0% | — | — | — | — | — | — |
| Gross profit | -$6.09M | $2.85M | $2.01M | $1.23M | $500K | $130K | — | — | — | — |
| Gross margin | -152.8% | 35.7% | 29.1% | 36.3% | — | — | — | — | — | — |
| Operating income | -$33.2M | -$28.6M | -$35.2M | -$34.0M | -$14.9M | -$13.3M | -$21.2M | -$27.0M | -$24.7M | -$27.6M |
| Operating margin | -833.4% | -359.2% | -510.2% | -1004.9% | — | — | — | — | — | — |
| Net income | -$33.2M | -$28.5M | -$35.1M | -$33.6M | -$14.9M | -$12.8M | -$13.9M | -$25.7M | -$23.5M | -$26.6M |
| Net margin | -832.6% | -358.1% | -508.9% | -994.1% | — | — | — | — | — | — |
| EPS (diluted) | -$0.84 | -$0.53 | -$4.23 | -$2.28 | -$0.72 | -$0.27 | — | -$0.50 | -$0.43 | -$0.43 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.1M | -$23.9M | -$29.8M | -$27.6M | -$16.8M | -$11.0M | -$18.8M | -$23.7M | -$20.8M | -$24.3M |
| Capital expenditures | $490K | $265K | $163K | $493K | $330K | $572K | $338K | $887K | $556K | $1.17M |
| Free cash flow | -$25.6M | -$24.2M | -$30.0M | -$28.1M | -$17.2M | -$11.5M | -$19.1M | -$24.6M | -$21.3M | -$25.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.9M | $7.84M | $4.47M | $11.3M | $3.18M | $69.6M | $45.1M | $20.7M | $18.4M | $16.2M |
| Total assets | $16.8M | $14.5M | $10.7M | $16.6M | $4.46M | $5.45M | $51.1M | $45.8M | $41.6M | $39.4M |
| Total liabilities | — | — | $7.60M | $9.32M | $5.13M | $2.99M | $6.82M | $25.0M | $24.0M | $23.7M |
| Shareholders' equity | $11.1M | $7.88M | $3.08M | $7.28M | $1.95M | $2.46M | $44.3M | $20.8M | $17.6M | $15.7M |
| Retained earnings | -$206M | -$234M | -$269M | -$305M | -$320M | -$58.9M | -$72.8M | -$98.4M | -$122M | -$149M |
| Shares (wtd avg diluted) | 42.7M | 57.6M | 9.54M | 15.6M | 23.2B | 36.8M | 50.7B | 50.9B | 55.0M | 62.4M |
Every figure is extracted from Vivani Medical, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.